P

Patricia Lepage

AgroParisTech

ORCID: 0000-0002-9501-6771

Publishes on Gut microbiota and health, Clostridium difficile and Clostridium perfringens research, Inflammatory Bowel Disease. 253 papers and 38.8k citations.

253Publications
38.8kTotal Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

A human gut microbial gene catalogue established by metagenomic sequencing
Junjie Qin, Ruiqiang Li, Jeroen Raes et al.|Nature|2010
Cited by 11.6kOpen Access

To understand the impact of gut microbes on human health and well-being it is crucial to assess their genetic potential. Here we describe the Illumina-based metagenomic sequencing, assembly and characterization of 3.3 million non-redundant microbial genes, derived from 576.7 gigabases of sequence, from faecal samples of 124 European individuals. The gene set, ∼150 times larger than the human gene complement, contains an overwhelming majority of the prevalent (more frequent) microbial genes of the cohort and probably includes a large proportion of the prevalent human intestinal microbial genes. The genes are largely shared among individuals of the cohort. Over 99% of the genes are bacterial, indicating that the entire cohort harbours between 1,000 and 1,150 prevalent bacterial species and each individual at least 160 such species, which are also largely shared. We define and describe the minimal gut metagenome and the minimal gut bacterial genome in terms of functions present in all individuals and most bacteria, respectively. The human body plays host to an estimated 100 trillion microbial cells, most of them in the gut where they have a profound influence on human physiology and nutrition — and are now regarded as crucial for human life. Gut microbes contribute to the energy harvest from food, and changes of gut microbiome may be associated with bowel diseases or obesity. Now the international MetaHIT (Metagenomics of the Human Intestinal Tract) project has published a gene catalogue of the human gut microbiome derived from 124 healthy, overweight and obese human adults, as well as inflammatory disease patients, from Denmark and Spain. The resulting data provide the first insights into this gene set — which is over 150 times larger than the human gene complement — and show that the genes are largely shared among individuals. Based on the variety of functions encoded by the gene set, it is possible to define both a minimal gut metagenome and a minimal gut bacterial genome. Deep metagenomic sequencing and characterization of the human gut microbiome from healthy and obese individuals, as well as those suffering from inflammatory bowel disease, provide the first insights into this gene set and how much of it is shared among individuals. The minimal gut metagenome as well as the minimal gut bacterial genome is also described.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Cited by 3.4kOpen Access

Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Cited by 2kOpen Access

Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT(H)17) cells and memory T(H)1 immune responses. Tumor-bearing mice that were germ-free or that had been treated with antibiotics to kill Gram-positive bacteria showed a reduction in pT(H)17 responses, and their tumors were resistant to cyclophosphamide. Adoptive transfer of pT(H)17 cells partially restored the antitumor efficacy of cyclophosphamide. These results suggest that the gut microbiota help shape the anticancer immune response.